One of the common illness found among women is migraine headaches. But because of the several health risks, these headaches can be difficult to treat amongst the elderly women. While the hormone therapy has been effective in treating many symptoms of menopause, safety of its use in women to treat migraine was unconfirmed. A new research based on the information from Women’s Health Initiative (WHI) showed the safe use of hormone therapy to treat migraine among women. The results of this study will be presented at The North American Menopause Society (NAMS) Annual Meeting in Philadelphia, from October 11 to 14.
There have been few research activities showing the effect of the hormone therapy on migraine and consequent cardiovascular disorders. Hormones have not been prescribed often for treating migraine sufferers due to the relation between use of exogenous estrogen and an additional risk of stroke among women who are suffering from migraine. This resulted to the recommendation that birth control pills should be use with caution or entirely avoided in women suffering from migraines.
During this new research, data on 67,903 participants were examined and analyzed to find out any relationship between cardiovascular disorders and migraines and the interaction with use of hormone therapy. It was seen that the women with migraine opted to exercise and drink less than those without suffering from migraines. These women had higher intake of calcium and vitamin D. They were also more vulnerable to have hot flashes and sweat nights. The overall result of the study was positive in terms of safety of use, as there was no effect of hormone therapy on the relationship between cardiovascular disorders and migraine.
Is hormone replacement therapy (HRT) worth the risks associated with it? Do its benefits of treating menopause symptoms outweigh the risks? These are the crucial questions right on the top of the minds of women looking to opt for HRT to treat osteoporosis, vaginal dryness, hot flashes, and the like. However, a new research published Tuesday in The Journal of the American Medical Association (JAMA) has a good news for menopausal women. JoAnn E. Manson, a lead author of the study, former North American Menopause Society (NAMS) president, and Harvard Medical School professor, has said hormone therapy had no association with all-cause mortality during the treatment and long-term follow-ups of the trials conducted.
Manson has also said that the findings of the new analysis should give a reassurance of hormone therapy being reasonable for symptomatic women in generally good health while in early menopause.
Menopausal Women and Doctors Reassured about Hormone Therapy
The Women’s Health Initiative hormone therapy trials are part of a randomized study that involved 27, 347 women who took hormone medicine while others were given a placebo. The trials have evaluated the risks and benefits of menopause hormone therapy taken by mainly healthy postmenopausal women to prevent chronic diseases. They tested estrogen plus progestin and estrogen alone–the most common sorts of hormone therapy.
The postmenopausal participants were 63 years old on an average at enrollment. The effect of treatment was explored between five to seven years along with 18 years of collective follow-up. The trials then explained how mortality rate was affected by hormone therapy. Alzheimer’s disease and other dementia deaths were considerably lower in participants who were given estrogen-alone than those given a placebo during the follow-up of 18 years.
NAMS director, Joann Pinkerton has said that the group does not recommend restricting hormone therapy to the shortest duration or lowest dose but finding the most suitable one for each woman. Pinkerton further said that there are fresher treatments available with potentially low risk of stroke or blood clots, such as transdermal patches.